Search Results - "Reina Zoilo, J. J."

Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study by Lopez Lopez, R., Reina Zoilo, J.J., Monge, D., Caballero, F., Guillem Porta, V., Aranda Aguilar, E., Carrato Mena, A., Diaz Rubio, E., Garcia Foncillas, J., Feyjoo, M., Camps, C.

Get full text

Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP) by Camps Herrero, C., Reina Zoilo, J. J., Monge Martín, D., Caballero Martínez, F., Guillem Porta, V., Aranda Aguilar, E., Carrato Mena, A., Díaz-Rubio García, E., García-Foncillas López, J., Feijóo Saus, M., López López, R.

“…Aims To prove if there is clinical inertia in the identification and treatment of episodes of breakthrough cancer pain (BTcP), comparing actual results from…”
Get full text

P-3 Real-world dosing patterns of regorafenib in patients with metastatic colorectal cancer in Spain: The RE-SEARCH study by Muñoz, A. López, González-Flores, E., Afonso, R., Maseda, A. Carral, Pimentel, P., López-López, C., Jimeno, R., Mateos, R. Fuentes, Zoilo, J. Reina

Get full text

P-60 Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy by Ramirez Daffos, P., Jiménez, E., Bolaños Naranjo, M., González-Astorga, B., Rubiales, S., Ceballos Barbancho, E., Rodríguez, J., Reina Zoilo, J.

Get full text

P-50 Prognostic factors in patients receiving trifluridine/tipiracil for refractory metastatic colorectal cancer in the real-life setting: The ROS study by García-Alfonso, P., Reina Zoilo, J., Mata Velasco, E., Llanos, M., Illán Varella, A., Safont Aguilera, M., Delgado Ureña, M., Castañón, C., Pimentel, P., Alonso Orduña, V., Mendez, J., Rivera Herrero, F., Siso, I., Rodriguez-Pascual, J., Grávalos Castro, C., Afonso, R., Fernandez Rañada, I., Grández, R., Moreno, M., López Muñoz, A., García-Paredes, B., Aranda, E.

Get full text

1709PAssessment and treatment of breakthrough cancer pain in Spain: A self-audit study by Lopez Lopez, R, Reina Zoilo, J J, Monge, D, Caballero, F, Guillem Porta, V, Aranda Aguilar, E, Carrato Mena, A, Diaz Rubio, E, Garcia Foncillas, J, Feyjoo, M, Camps, C

Get full text

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study by Sastre, J., García-Alfonso, P., Viéitez, J.M., Cano, M.T., Rivera, F., Reina-Zoilo, J.J., Salud-Salvia, A., Quintero, G., Robles-Díaz, L., Safont, M.J., La Casta, A., Gil, S., Polo, E., Asensio-Martínez, E., García-Paredes, B., López, R.L., Guillot, M., Valladares-Ayerbes, M., Aranda, E., Díaz-Rubio, E., Viéitez, J.M., Jiménez, P., Aguilar, E. Aranda, Gómez, A., Gil Calle, S., Salud, A., Valladares, M., Graña, B., García-Alfonso, P., Rivera, F., Quintero, G., Reina, J.J., González Flores, E., Salgado, M., Grande, E., Guillén, C., Garcia Carbonero, R., Flor, M.J., Safont, M.J., La Casta, A., Arévalo, S., Sastre, J., López López, R., Manzano, H., Guillot, M., Hernández Yagüe, X., Arrivi, A., Falcó, E., Gallego, J., Escudero, P., Cabezas, I., Juárez, A., Gálvez, E., Grávalos, C., Robles, L., Polo, E., Dueñas, R., Campos, J.M., Albert, A., Salinas, P., Montagut, C., Provencio, M., Ruiz Casado, A., Muñoz, J., Gil Raga, M., Chilet, M.R., González González, F.J., Massutí, B., López, A., Aparicio, J., Marín, M., Alfaro, J., Zanui, M., Gutiérrez Abad, D., García Tapiador, A.M., García-Girón, C., Molina Saera, J., Torres Sánchez, E., López, I., Bosch, C., Valero, J., Martínez de Prado, P.

“…We explored the influence of BRAF and PIK3CA mutational status on the efficacy of bevacizumab or cetuximab plus 5-fluorouracil/leucovorin and irinotecan…”
Get full text

593PDihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: A single Spanish hospital experience by Rambla, M D Mediano, Marcos, J A, Carrillo, R, Espinosa, M, Sanchez, F, Alvardado, M D, Rendon, L, Zoilo, J J Reina, Albero, A

“…Abstract Background Severe toxicity as a result of Fluoropyrimidine treatments appears in up 30% of patients. The reduce activity of DPD is one of the main…”
Get full text

593P - Dihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: A single Spanish hospital experience by Rambla, M D Mediano, Marcos, J.A., Carrillo, R., Espinosa, M., Sanchez, F., Alvardado, M.D., Rendon, L., Zoilo, J J Reina, Albero, A.

“…Severe toxicity as a result of Fluoropyrimidine treatments appears in up 30% of patients. The reduce activity of DPD is one of the main cause of severe adverse…”
Get full text

Dihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: A single Spanish hospital experience by Rambla, M D Mediano, Marcos, J.A., Carrillo, R., Espinosa, M., Sanchez, F., Alvardado, M.D., Rendon, L., Zoilo, J J Reina, Albero, A.

Get full text

Primary endobronchial non-hodgkins lymphoma: description of a case and review of the literature by Reina Zoilo, J J, Ruiz Borrego, M, Valenzuela Claros, J C, Valladares Ayerbes, M J, Borrega García, P, Viana Alonso, A, Moreno Nogueira, J A

“…We report a case of primary endobronchial non-Hodgkin Lymphoma, an unusual extranodal lymphoma, in a 62 year old patient, which begins with malaise, marked…”
Get more information

Acute liver failure as presentation form of small cell carcinoma of the lung by Valladares Ayerbes, M J, Cañadas Garcia de León, M, Reina Zoilo, J J, Valenzuela Claros, J C, Ruiz Borrego, M, Barea Bejarano, J L

“…Metastatic infiltration of the liver is an uncommon cause of acute hepatic failure. We describe the case of a 55-yr-old man who presented with signs and…”
Get more information

Effectiveness and safety of imatinib in seven gastrointestinal stromal tumor cases by Giménez Castellanos, J, Sánchez Gómez, E, Reina Zoiló, J J, Gabella Bazarot, E, Marín Ariza, I, Grutzmancher Saiz, S

“…To measure the effectiveness and safety of imatinib for gstrointestinal stromal tumors (GISTs). A retrospective study from 1993 through June 2005 by…”
Get full text

Human recombinant erythropoietin in the treatment of the anemia of multiple myeloma by Valladares Ayerbes, M J, Valenzuela Claros, J C, Reina Zoilo, J J, Ruiz Borrego, M, Moreno Nogueira, J A

Get more information